| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2026 Q2 | Jul 27, 2026 | abrdn U.S. Small Cap Equity Fund | 26.2% | 27.5% | ATMU, BLBD, COHU, CPRX, CRDO, DFIN, ELF, FROG, MGY, MTRN, TVTX, UTI | AI, Biotechnology, defense, Infrastructure Spending, Onshoring, semiconductors, small caps, US | UTI TVTX BLBD COHU MTRN FROG |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Fund Letters | abrdn U.S. Small Cap Equity Fund | Travere Therapeutics, Inc. | Biotechnology | Biotechnology | Bull | NASDAQ | biotechnology, Kidney Disorders, Label Expansion, Metabolic Disorders, Orphan drugs, pipeline development, rare diseases, Specialty pharma | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||